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A B S T R A C T
Pseudomonas aeruginosa is a gram-negative pathogen, which causes life-threatening infections in im-
munocompromized patients. These bacteria express a secreted lipoxygenase (PA-LOX), which oxygenates free
arachidonic acid to 15S-hydro(pero)xyeicosatetraenoic acid. It binds phospholipids at its active site and phy-
sically interacts with lipid vesicles. When incubated with red blood cells membrane lipids are oxidized and
hemolysis is induced but the structures of the oxygenated membrane lipids have not been determined. Using a
lipidomic approach, we analyzed the formation of oxidized phospholipids generated during the in vitro in-
cubation of recombinant PA-LOX with human erythrocytes and cultured human lung epithelial cells. Precursor
scanning of lipid extracts prepared from these cells followed by multiple reaction monitoring and MS/MS
analysis revealed a complex mixture of oxidation products. For human red blood cells this mixture comprised
forty diﬀerent phosphatidylethanolamine and phosphatidylcholine species carrying oxidized fatty acid residues,
such as hydroxy-octadecadienoic acids, hydroxy- and keto-eicosatetraenoic acid, hydroxy-docosahexaenoic acid
as well as oxygenated derivatives of less frequently occurring polyenoic fatty acids. Similar oxygenation products
were also detected when cultured lung epithelial cells were employed but here the amounts of oxygenated lipids
were smaller and under identical experimental conditions we did not detect major signs of cell lysis. However,
live imaging indicated an impaired capacity for trypan blue exclusion and an augmented mitosis rate. Taken
together these data indicate that PA-LOX can oxidize the membrane lipids of eukaryotic cells and that the
functional consequences of this reaction strongly depend on the cell type.
1. Introduction
Lipoxygenases (LOX) catalyze oxygenation of polyunsaturated fatty
acids to hydroperoxy derivatives. In plants and non-mammalian ani-
mals downstream products of these hydroperoxides are important for
wound healing and defense against pests [1]. In mammals, they play
extensive roles in inﬂammation [2,3]. Pseudomonas aeruginosa (PA) is
one of the most common gram-negative bacteria, and is responsible for
a variety of life-threatening infections in immunocompromized in-
dividuals [4]. PA is one of the rare bacterial species that expresses a
secretory lipoxygenase [5]. Although PA-LOX has extensively been
characterized with respect to its enzymatic [6–9] and structural prop-
erties [8,10–12], its biological relevance remains unclear. There are
several hypotheses for the biological role of this enzyme but none has
conclusively been proven. i) Bioﬁlm formation: Expression of PA-LOX is
upregulated when bacteria switch to bioﬁlm formation and increased
PA-LOX expression might impact bioﬁlm growth by altering lipid sig-
naling between host and pathogen [7]. ii) Virulence factor: In vitro
studies employing PA-LOX-expressing versus PA-LOX-deﬁcient patho-
gens and cultured lung epithelial cells have suggested that the invasive
capacity of the pathogen improves when PA-LOX is expressed [11].
These data suggest a role for PA-LOX as a virulence factor and recent
studies of PA-LOX-erythrocyte interactions support this hypothesis
[13]. iii) Bacterial evasion strategy: PA-LOX exhibits lipoxin synthase
activity [8]. If formed in vivo these anti-inﬂammatory and pro-resolving
mediators might downregulate the immune response of the host. The
formation of such products augments the likelihood of pathogen sur-
vival and thus, lipoxin synthase activity might be considered part of a
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bacterial evasion strategy [8]. iv) Oxygen sensor: In contrast to most
mammalian LOXs, which have Km values for oxygen in the lower μM
range [14–17], PA-LOX exhibits a low oxygen aﬃnity with Km above
400 μM [8]. These data indicate that at physiological dioxygen con-
centrations, the enzyme does not work at substrate saturation and thus,
variations of the actual oxygen concentrations are directly translated
into changes of catalytic activity. Such kinetic properties are char-
acteristic of oxygen sensing proteins, such as FixL [18] and HIF-prolyl
hydroxylase [19,20]. Consequently, PA-LOX might function as bacterial
oxygen sensor.
One of the most striking properties of PA-LOX is its destructive
character. When human erythrocytes are incubated in vitro with pure
recombinant PA-LOX, hemolysis is induced [13]. After a 24 h incuba-
tion period almost 50 % of all erythrocytes present in the incubation
mixture were destroyed [13]. In contrast, only 1–2 % of the ery-
throcytes were lyzed in control incubations with pure native rabbit
ALOX15 [13]. These data suggest that the secretory PA-LOX permea-
bilizes red blood cell membranes and this functional consequence has
been related to the oxidation of membrane lipids [13]. However, the
chemical structure of the oxidized membrane phospholipids has not
been explored. Moreover, it has not been tested whether the enzyme
can also oxidize plasma membrane lipids of nucleated host cells and it
remains unclear what structural or functional consequences such
membrane lipid oxygenation might have. To address these questions,
we incubated pure recombinant PA-LOX with human erythrocytes and
human alveolar epithelial cells and analyzed the membrane phospha-
tids using a lipidomic approach (HPLC, LC-MS/MS). We found that the
membrane lipids of both, human erythrocytes and human alveolar
epithelial cells are oxygenated by recombinant PA-LOX. Similar pat-
terns of oxidized membrane phospholipids are formed, but erythrocytes
are more susceptible as indicated by higher amounts of oxygenation
products formed under comparable experimental conditions. The
principle capacity of PA-LOX to oxidize plasma membrane lipids of
eukaryotic cells supports the hypothesis [11] that the enzyme might
function as virulence factor during P. aeruginosa infections.
2. Materials and methods
2.1. Chemicals
All chemicals used for this study were obtained from the following
sources: acetic acid from Carl Roth GmbH (Karlsruhe, Germany); so-
dium borohydride from Life Technologies, Inc. (Eggenstein, Germany);
antibiotics and isopropyl-β-thiogalactopyranoside (IPTG) from Carl
Roth GmbH (Karlsruhe, Germany), restriction enzymes from Thermo
Fisher Scientiﬁc-Fermentas (Schwerte, Germany); the E. coli strain BL21
(DE3) from Invitrogen (Carlsbad, USA) and E. coli strain XL-1 from
Stratagene (La Jolla, USA). Oligonucleotide synthesis was performed at
BioTez Berlin Buch GmbH (Berlin, Germany). Nucleic acid sequencing
was carried out at Euroﬁns MWG Operon (Ebersberg, Germany). HPLC
grade methanol, chloroform, and water were from Fisher Scientiﬁc. 1,2-
dipentadecanoyl-sn-glycero-3-phosphocholine (PC(15:0/15:0)) and 1,2-
dipentadecanoyl-sn-glycero-3-phosphoethanolamine (PC(15:0/15:0))
from Avanti Polar Lipids (Alabaster, USA). All other reagents were from
Sigma-Aldrich, unless otherwise stated. Human lung epithelial cells
(A549) were purchased from ATCC and cultured according to the re-
commendations of the vendor.
2.2. Isolation of human erythrocytes
5 ml of blood was drawn from a healthy volunteer in a tube con-
taining 25 mM EDTA to prevent coagulation. The blood was then cen-
trifuged at 1500 rpm and 4 °C for 10 min and the plasma was recovered.
The red blood cells were then washed twice with 10 ml of PBS at
1000 rpm and 4 °C for 10 min, the supernatant was discarded and the
packed erythrocyte pellet was used for incubation with PA-LOX. The
ethics committee of Charite approved blood collection under the
number EA1/052/16.
2.3. Enzyme expression and puriﬁcation
The prokaryotic expression plasmid pET28a(± ) containing the
coding sequence of WT-PA-LOX was kindly provided by Prof. Xavi
Carpena (Institut de Biologia Molecular, Parc Cientíﬁc de Barcelona,
Baldiri Reixac 10, 08028 Barcelona, Spain). The ﬁnal construct was
devoid of the signal peptide and contained instead the hexa-His-tag
required for eﬃcient puriﬁcation. The protein sequence began from the
last amino acid (alanine) of the predicted signal sequence. This plasmid
was then ampliﬁed for further analysis in E. coli XL-1 blue cells and then
extracted using the Nucleobond Xtra Midi Plus kit (Macherey-Nagel,
Düren, Germany). PA-LOX was expressed in E. coli using the Enpresso B
kit (BioSilta Ltd., St. Ives, Great Britain) in the following manner:
200 ng of the plasmid DNA was transformed into 100 μl of E. coli BL21
(DE3) cells and grown on kanamycin agar plates. After incubation over
night at 37 °C, a 2 ml pre-culture (LB medium with 50 μg/ml kana-
mycin) was inoculated and grown for 6–8 h at 37 °C and 180 rpm. As
recommended by the supplier, the pre-culture was then added to a
50 ml main culture to achieve an OD600 between 0.1 and 0.15 and
grown over-night at 30 °C and 250 rpm. Expression of PA-LOX was
induced in E. coli by adding 1 mM (ﬁnal concentration) IPTG to the
main culture and incubated over night at 25 °C and 250 rpm. Bacteria
were harvested by centrifugation and the resulting pellet was recon-
stituted in 5 ml PBS. Bacteria were lyzed by sonication (digital soniﬁer,
W-250D Microtip Max 70 % Amp, Model 102C (CE); Branson
Ultraschall, Fürth, Germany), cell debris was removed by centrifugation
and the lysate supernatant was employed for further puriﬁcation.
The recombinant His-tag fusion protein was puriﬁed by nickel
agarose aﬃnity chromatography using Protino Ni-NTA-agarose sus-
pension (Machery Nagel, Düren, Germany). For this, 5 ml of cell lysate
supernatant was incubated with 500 μl of the Ni-NTA beads on a ro-
tator, rotamix RMI (ELMI, Riga, Latvia), for 1 h, at 4 °C. The gel beads
were then transferred to an open bed chromatography column (Bio-
Rad, München, Germany). Puriﬁcation of PA-LOX involved washes with
three kinds of buﬀers with varying imidazole concentrations. To re-
move non-speciﬁcally bound proteins, the column was ﬁrst eluted
thrice with 800 μl wash buﬀer 1 containing 10 mM imidazole. Next, the
column was washed three times with 800 μl of wash buﬀer 2 containing
25 mM imidazole to elute weakly bound proteins. Finally, rinsing the
column seven times with 300 μl of elution buﬀer containing 200 mM
imidazole eluted the desired recombinant protein. Usually, the majority
of the PA-LOX was recovered in the elution fractions 1, 2 and 3.
The excessive imidazole ions present in the elution fractions were
removed by size exclusion chromatography using Econo-Pac 10DG
desalting columns (Bio-Rad, California, USA). PA-LOX was then sub-
sequently concentrated to the required protein concentrations by cen-
trifugation at 4000 rpm through an Amicon Ultra-15 10K centrifugal
ﬁlter (Millipore, Massachusetts, USA).
2.4. Oxygenation of red blood cells by PA-LOX
The ability of PA-LOX to oxygenate intact cells was determined by
subjecting puriﬁed PA-LOX to in vitro incubations with isolated human
erythrocytes. Packed human erythrocytes (0.1 ml) were incubated with
an aliquot of puriﬁed PA-LOX in 1 ml PBS at 25 °C under continuous
agitation. A similar assay mixture was carried out in the absence of PA-
LOX as non-enzymatic controls. After the desired incubation periods, an
aliquot of the sample mixture was spun down and the hemoglobin
content in the supernatant was determined by measuring the absor-
bance of the Soret band at 410 nm (see below). The remaining reaction
mixture was subjected to lipid extraction according to [13].
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2.5. Oxygenation of cultured A549 cells by PA-LOX
The ability of PA-LOX to oxygenate the membranes of functional
nucleated cells was tested by incubating near conﬂuent A549 cells in 6
well plates with pure recombinant PA-LOX (250 μg protein/ml, 2 ml
culture medium per well). After a 24 h incubation period, the cells were
harvested and cell survival was quantiﬁed by trypan blue exclusion.
From the remaining cells, the lipids were extracted and the extracts
analyzed for the presence of oxygenated phospholipids or subjected to
alkaline hydrolysis to quantify the hydroxy fatty acid/fatty acid ratio as
suitable measure for the degree of membrane lipid oxidation.
2.6. Alkaline hydrolysis
In order to quantify the free oxygenated and non‑oxygenated fatty
acids on HPLC, lipid extraction was followed by alkaline hydrolysis. For
this purpose, the bottom chloroform phase of the extracted lipids was
evaporated and reconstituted in 100 μl of methanol. 20 μl of 40 % (v/v
in water) KOH were added and the ester lipids were hydrolyzed under
argon atmosphere for 20 min at 60 °C. The samples were then cooled
down on ice for 5 min and acidiﬁed with 50 μl of acetic acid. After
incubating the samples on ice for 20 min, precipitate was removed by
centrifugation at 12,000 rpm for 10 min at 4 °C. The free fatty acid
derivatives present in the membrane lipids were then analyzed on RP-
HPLC following the chromatograms at 235 nm (oxygenated PUFAs) and
210 nm (non‑oxygenated PUFAs) to quantify the OH-PUFA/PUFA ratio.
2.7. Hemolysis assay
Hemolysis assays were carried out as described in [12] quantifying
the release of hemoglobin into the incubation supernatant. For this
purpose 0.1 ml of packed human erythrocytes were incubated in 1 ml
PBS at 25 °C in the absence or presence of diﬀerent amounts of PA-LOX.
After incubations the cells were spun down and the supernatant was
recovered. The cell pellet was reconstituted in 1 ml of water and os-
motic hemolysis was performed on ice for 45 min. The heme content
(absorbance of the Soret band at 410 nm) was determined in the in-
cubation supernatant (hemolysis related to LOX activity) and in the
osmotic hemolysis supernatant and the sum of these two measures was
set 100 % hemolysis.
2.8. Lipid extraction for LC-MS/MS
Hydroperoxides were reduced to their corresponding stable alcohols
by the addition of 1 mM SnCl2 for 10 min on ice. Where quantiﬁed,
10 ng each of PC(15:0/15:0), and PE(15:0/15:0) was added to the
samples before extraction, as internal standards. Lipids were extracted
by adding 2.5 ml of methanol and 1.25 ml of chloroform to 1 ml of
sample, followed by 1 min vortex and incubation on ice for 15 min.
Then, 1.25 ml of chloroform and 1.25 ml of water was added. After
vortexing and centrifugation, lipids were recovered in the bottom
chloroform layer. The chloroform layer was dried, dissolved in me-
thanol, and stored at −80 °C before analysis by LC/MS/MS.
2.9. Precursor and Neutral Loss Scanning
Spectra were acquired, following direct infusion, with a ﬂow rate of
10 μl min−1. Precursor scanning LC/MS/MS in negative mode was
carried out scanning Q1 from 650 to 950 atomic mass units (amu) with
total scan time (including pauses) over 2.2 s with Q3 set to daughter ion
of interest. Settings were DP−50 V, EP−10 V, CE−42 V and CXP at
−13. For positive scanning, polarity was reversed.
2.10. Reverse-phase LC-MS/MS of phospholipids
Lipid extracts were separated by reverse-phase HPLC using a Luna
3 μm C18 [2] 150 × 2-mm column (Phenomenex, Torrance, CA) with a
gradient of 50 – 100 % B over 10 min followed by 30 min at 100 % B
(A, methanol: acetonitrile : water, 1 mM ammonium acetate, 60:20:20;
B, methanol, 1 mM ammonium acetate) with a ﬂow rate of
200 μl min−1. Products were monitored by LC/MS/MS in negative ion
mode, on a 6500 Q-Trap (Sciex, Cheshire, United Kingdom) using the
speciﬁc parent to daughter transitions. ESI-MS/MS conditions were:
TEM 500 °C, GS1 40, GS2 30, CUR 35, IS−4500 V, dwell time 75 s, DP
−50 V, EP−10 V, CE−38 V and CXP at−11 V. 15-HETE-PE and PC
lipids were quantiﬁed using standard curves generated by varying
18:0a/15-HETE-PE or 16:0a/15-HETE-PC, with a ﬁxed amount of PE
(15:0/15:0) and PC(15:0/15:0), using the daughter ion (m/z 319.2) for
the 15-HETE [21]. Product ion spectra were obtained at the apex of the
MRM transitions, with the MS operating in ion trap mode. Scans were
acquired with a linear ion trap ﬁll time of 75 ms and Q0 trapping. The
LC-MS data were evaluated statistically (Tukey's Honestly Signiﬁcant
Diﬀerences post-hoc test), which is indicated by the error bars in the
supplemental ﬁgures. The degrees of signiﬁcance between PA-LOX
treatment corresponding control incubations are given in Fig. 6.
2.11. Construction of heatmaps
For generation of the heatmaps, the analyte/standard ratios were
evaluated using the pheatmap package in R. The pheatmap method
used for this purpose is based on Euclidean metric to establish the
treatments' relationships depicted as clusters. The clusters are ag-
gregated following the “shortest distance” rule. In the heatmaps the
levels of treatment response are represented by a color gradient ranging
from blue (decrease in response) to white (no change) to red (increase
in response). Lipids are color-coded by group and clustered by simi-
larity in overall response to PA-LOX. Lipids were normalized to basal
levels, at 12 h. The fold change was calculated by dividing the con-
centration of each lipid in samples after PA-LOX treatment to the
controls. The correlations of fold changes of lipids were estimated by
spearman test. Correlation plot was built by using ‘corrplot’ package,
version 3.3.1.
2.12. HPLC analysis of the hydroxy fatty acids/fatty acid ratio (OH-PUFA/
PUFA)
To calculate the hydroxy fatty acid/fatty acid ratio as suitable
measure for the degree of membrane lipid oxidation, RP-HPLC analyses
were carried out with the hydrolysis mixtures of the membrane lipids.
For this purpose, a Shimadzu instrument equipped with a Hewlett
Packard diode array detector 1040 A and a Nucleodur C18 Gravity
column (Marchery-Nagel, Düren, Germany; 250 × 4 mm, 5 μm particle
size), coupled with a guard column (8 × 4 mm, 5 μm particle size), was
used. A ﬂow of 1 ml/min was maintained throughout the run. The
hydroxy fatty acids (15-HETE + 13-HODE) were quantiﬁed following
the absorbance at 235 nm. In contrast, the major polyenoic fatty acids
(arachidonic acid + linoleic acid) were quantiﬁed at 210 nm and then
the hydroxy fatty acid/PUFA ratio was calculated [22]. The employed
HPLC system we did not completely resolve the diﬀerent HETE and
HODE isomers and thus separate quantiﬁcation of them was not pos-
sible. However, since the molar extinction coeﬃcient of conjugated
dienes is the same for all HODE and HETE isomers one can exactly
calculate the molar concentrations of conjugated dienes in the lipid
extracts despite the incomplete separation. However, the situation was
diﬀerent for the non-oxidized PUFAs. Here linoleic acid was not com-
pletely separated from arachidonic acid but for these two fatty acids the
molar extinction coeﬃcients are diﬀerent (diﬀerent numbers of double
bonds). To minimize the degree of inaccuracy we evaluated the joint
linoleic acid/arachidonic acid HPLC peak using a mixed molar extinc-
tion coeﬃcient assuming a 1:1 distribution of the two fatty acids. This
mixed coeﬃcient was then employed for quantiﬁcation of all chroma-
tograms. Although the absolute values of the OH-PUFA/PUFA ratios we
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calculated according to this algorithm might not be very accurate the
relative diﬀerences between hydrolyzed and non-hydrolyzed samples
on one hand and between PA-LOX treated and untreated samples on the
other are rather precise.
2.13. Life imaging and quantiﬁcation of the mitosis rate
Life imaging was conducted in the Advanced Medical BioImaging
Core Facility (AMBIO), University Medicine Berlin, Germany.
To follow the structural and functional alterations of A549 cells
during PA-LOX treatment, the cells were seeded into an 8 well μ-Slide
with glass bottom (ibidi GmbH, Planegg, Germany). After they became
pre-conﬂuent, the objective (20× DIC) of the microscope (A1Rsi
+ Confocal System with Nikon Eclipse T konfocal microscope and DIC
using a laser beam of 488 nm) was adjusted to one randomly selected
spot in each of the eight wells and initial images were taken. Then pure
PA-LOX (250 μg/ml, 200 μl incubation volume) was added to well 5–8
(PA-LOX sample) and an equal volume of PBS was added to the non-
enzyme control sample (well 1–4). The second set of images was taken
5 min after enzyme addition and further images were taken every 5 min
during the ﬁrst hour of the incubation period. Afterwards, the imaging
frequency was reduced to one image per 15 min.
Evaluation of the mitosis frequency was carried out in a blinded
way. For each well, four diﬀerent spots were randomly selected, and the
mitosis events were counted over the duration of the incubation period
(NIS-Elements viewer 4.20). This counting was repeated 3-times, so
that 12 counts were obtained for each spot. Since 4 diﬀerent wells have
been videotaped for the control incubations, 48 counts of the mitosis
events were obtained. Corresponding numbers were also obtained for
the PA-LOX samples. For statistic evaluation, the two-sided Students t-
test was used.
3. Results
3.1. In vitro incubation of human erythrocytes with pure recombinant PA-
LOX
When human erythrocytes were incubated with recombinant PA-
LOX for diﬀerent times, signiﬁcant hemolysis was observed. Under our
experimental conditions (70 μg/ml PA-LOX with 100 μl packed red
blood cells dissolved in 1 ml PBS), 2.1 ± 0.3 % of the erythrocytes
were disrupted as determined by hemoglobin release during 12 h of
incubation. After 24 h the degree of hemolysis increased to about
10.0 ± 1.9 %. Consistent with previous reports there was no hemolysis
(< 0.5 %) in control incubations carried out in the absence of PA-LOX
[13].
To explore the molecular basis of PA-LOX-induced hemolysis, we
analyzed by RP-HPLC the red cell membrane lipid extracts for oxyge-
nated polyenoic fatty acids, following alkaline hydrolysis of the ester
lipids (Fig. 1A-I). Recording the chromatogram at 235 nm we detected
13-HODE and 15-HETE as dominant oxygenation products. These
products were almost absent in enzyme-free controls (Fig. 1B-I). When
we recorded the chromatograms at 210 nm the parent PUFA were
quantiﬁed (Fig. 1A-II and B-II) and from the areas of the HETE/HODE-
and the linoleic acid + arachidonic acid peaks we calculated the OH-
PUFA/PUFA ratio. For this purpose, the chromatographic scales at 210
and 235 nm were calibrated by injecting known amounts of authentic
standards. Six point calibration curves for linoleic acid, arachidonic
acid and 13-HODE were established. The OH-PUFA/PUFA ratio, which
quantiﬁes the degree of oxidation of the membrane lipids, was con-
sidered a suitable measure for oxidative challenge of the plasma
membrane lipids. After a 24 h incubation, a OH-PUFA/PUFA ratio of
19.1 % was observed indicating that by 24 h one out of ﬁve linoleic
acid/arachidonic acid residues was present as hydroxylated derivative.
To explore whether the OH-PUFA-isomers are present in the lipid
extracts as free oxygenated fatty acids or as constituents of the
membrane ester lipids we analyzed an aliquot of the non-hydrolyzed
lipid extracts. Here we found that the OH-PUFA content was below the
detection limit of our assay system. In fact, we did not see signiﬁcant
HPLC peaks in the HETE/HODE region. Although these data do not
exclude that small amounts of free HODE/HETE are present in the lipid
extracts the majority of oxygenated PUFAs are present in the membrane
ester lipid fraction.
To ﬁnd out whether the degree of hemolysis was related to the OH-
PUFA/PUFA ratio, we employed a second enzyme preparation and re-
peated the hemolysis experiment (Table 1). Here 2 μg/ml of PA-LOX
induced signiﬁcant hemolysis (18.6 %) after a 24 h incubation. With
7 μg/ml of PA-LOX, a similar degree of hemolysis was observed but at
these enzyme concentrations we did not detect the formation of OH-
Fig. 1. Oxygenation of linoleic acid and arachidonic acid esteriﬁed in the membrane
phospholipids of intact erythrocytes to 13-HODE and 15-HETE by puriﬁed PA-LOX.
Puriﬁed PA-LOX (2 μg, 7 μg, 60 μg, 170 μg and 500 μg) was incubated with 100 μl of
packed erythrocytes in 1 ml of PBS (pH 7.4) at 25 °C for 24 h under continuous agitation.
Similar incubations of the erythrocytes were carried out in the absence of PA-LOX as non-
enzyme controls. After 24 h, the reaction mixtures were subjected to lipid extraction. The
bottom chloroform phase was recovered, the solvent was evaporated and the remaining
lipids were reconstituted in methanol. The extracted lipids were then hydrolyzed under
alkaline conditions and analyzed by RP-HPLC to determine the major oxygenation pro-
ducts formed in the A) non-enzymatic control and B) PA-LOX containing sample. Similar
chromatograms were obtained for all PA-LOX concentrations (ﬁve samples) but only the
chromatogram for the 500 μg incubation is shown. Inset: UV-spectra of the conjugated
dienes taken at the chromatographic time points indicated by a and b.
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PUFA. When we added higher amounts of PA-LOX the degree of he-
molysis increased and we detected signiﬁcant amounts of OH-PUFAs so
that a OH-PUFA/PUFA-ratio could be calculated (Table 1). These data
indicate that there is no strict correlation between the formation of
oxygenated PUFAs and hemolysis. There are several ways to explain
this unexpected ﬁnding (see Discussion).
3.2. Precursor-LC-MS/MS scanning of human erythrocyte lipid extracts
The time-dependent increase in the OH-PUFA/PUFA ratio during
incubation of intact red blood cells with recombinant PA-LOX as well as
the speciﬁc pattern of the hydroxylated fatty acids [13] suggested
oxygenation of membrane lipids. Thus, we determined the phospholipid
composition of the erythrocyte membrane following incubation with
PA-LOX. Lipid extracts from 12 h incubations with/without PA-LOX
were analyzed for PE, PC, PI and PS molecular species using precursor
ion or neutral loss scanning LC-MS/MS (Fig. 2). Analysis at m/z 196
(negative ion mode, glycerol phosphoryl ethanolamine – H2O), m/z 241
(negative ion mode, glycerol phosphoryl inositol – H2O), m/z 184
(positive ion mode phosphoryl choline) and neutral loss scanning at m/
z 87 (negative ion mode, serine – H2O) revealed a large number of ions,
the intensities of which either decreased or increased following PA-LOX
treatment (Fig. 2). In addition, precursor ion scanning at m/z 303.3 and
m/z 279.1 was used to identify phospholipids containing either ara-
chidonic acid or linoleic acid respectively, which were decreased fol-
lowing PA-LOX treatment (Fig. 3).
Next, we performed negative precursor-LC-MS/MS at m/z 319.2 and
295.1. These ions represent the carboxylate anion of hydro-
xyeicosatetraenoic acid (HETE) and hydroxyoctadecadienoic acid
(HODE), respectively. Precursor scans m/z at 319.2 indicated that a
number of phosphatidylethanolamine (PE) and phosphatidylcholine
(PC) species containing HETE-isomers were formed during PA-LOX/
erythrocyte interaction (Fig. 4A). The m/z 738, 754, 764, 766 and 782
suggested 16:0p/15-HETE-PE, 16:0a/15-HETE-PE, 18:1p/15-HETE-PE
and 18:0p/15-HETE-PE [M-H]− (Fig. 4A). Similarly, precursor scans at
m/z 295.1 (Fig. 4B) indicated the formation of HODE-containing
phospholipids.
3.3. Structural elucidation of oxidized phospholipids formed by PA-LOX
acting on human erythrocytes
Next, we carried out LC-MS/MS to structurally identify the major
lipid species generated during PA-LOX induced oxidation of mem-
branes, and established a multiple reaction monitoring (MRM) method
to enable their semi-quantitative analysis. Employing this protocol we
monitored 70 diﬀerent phospholipid species and heatmaps, containing
normalized data, summarize the diversity of these membrane lipids
(Fig. 5).
First, we quantiﬁed non‑oxygenated phospholipids carrying poly-
enoic fatty acids. These lipids constitute potential PA-LOX substrates
and should be reduced during PA-LOX incubation.
Phosphatidylethanolamines containing saturated or monounsaturated
fatty acids identiﬁed such as oleate (18:1, n-1), stearate (18:0) and
palmitate (16:0) did not decrease during PA-LOX incubation
(Supplemental Fig. S1AeC). In contrast, phospholipids containing the
polyenoic fatty acids arachidonic acid (20:4, n-6), linoleic acid (C18:2,
n-6), dihomo-gamma-linolenic acid (20:3, n-6), adrenic acid, (22:4, n-
6) and docosahexaenoic acid (22:6, n-3; DHA) all decreased during PA-
LOX incubation (Fig. 5, left panel). More detailed bar diagrams invol-
ving full reaction kinetics and experimental error bars for these lipids
are shown in supplemental Fig. S1-1 and S1-2. Some of these images
suggest that fatty acids at the sn1 position appeared to contribute to PA-
LOX substrate selectivity. In fact, phospholipids with a C18:1 fatty acid
at the sn-1 position are preferentially oxygenated when compared with
corresponding lipids carrying C18:0 or C16:0 residues (compare panels
I with H and L in Fig. S1-1 and panels A1 with W and Y in Fig. S1-2).
When the diﬀerent non-oxidized phospholipid species were grouped
according to the extent of alterations they experience during a 12 h
incubation period with PA-LOX, three diﬀerent lipid clusters can be
separated (Fig. 5, left panel). Interestingly, the upper cluster (most se-
vere alterations) exclusively involves phosphatidylethanolamine spe-
cies. In contrast, the middle cluster involves mainly phosphatidylcho-
line lipids whereas phosphatidylinositols and two
phosphatidylethanolamines form the lower cluster. Examination of the
lipids in the absence of PA-LOX (comparison of 12 vs. 24 h control
samples) reveals that most phosphatidylethanolamines (cluster 1) are
relatively stable during the incubation. In contrast, phosphatidylcho-
lines (cluster 2) decrease while the cluster 3 lipids increase. These data
suggest PA-LOX independent phospholipid remodeling. Comparing the
eﬀect of PA-LOX on diﬀerent phospholipid subfamilies, we found that
most phosphatidylethanolamines (cluster 1 lipids) decreased dramati-
cally during 12 h of PA-LOX treatment, which is consistent with their
oxidation. Interestingly they recovered somewhat by 24 h. In contrast,
cluster 2 (phosphatidylcholines) and cluster 3 (phosphatidylinositols)
lipids also decreased during 12 h PA-LOX treatment, but do not recover
(Fig. 5, left panel).
Next, we quantiﬁed phospholipid species carrying oxygenated
polyenoic fatty acids (Fig. 5, right panel). These include the arachidonic
acid oxygenation products 15-HETE and 15-KETE, the linoleic acid
oxygenation products 13/9-HODE and the oxygenation products of
docosahexaenoic acid (HDoHE), docosatetraenoic acid, doc-
osapentaenoic acid and eicosatrienoic acid (Figs. 5, 6 and Fig. S4).
Detailed bar diagrams involving full reaction kinetics and experimental
error bars for these oxidized lipids are shown in supplemental Figs.
S2–4. From these images it can be seen, that oxidized lipids were vir-
tually undetectable in the absence of PA-LOX. However, after 12 h and
24 h of incubation in the presence of recombinant PA-LOX large
amounts of oxidized phospholipids were detected (Fig. 5). These data
indicate that direct oxidation of phospholipids in cell membranes can
be triggered by PA-LOX. The total amounts of esteriﬁed HETE found in
the analyzed oxidized phospholipid species, which was generated in
response to 385 μg of puriﬁed PA-LOX during a 12-h incubation period,
was 5.44 ± 0.53 μg per 100 μl of packed red blood cells (Supplemental
Fig. S2). Following 24 h-treatment, this level was reduced by ~42 % to
3.18 ± 0.21 μg per 100 μl of packed red blood cells. This kinetic de-
cline in the concentration of oxidized phospholipids might be related to
the instability of their hydroperoxy lipid intermediates and/or to cel-
lular repair mechanisms removing oxidized membrane phospholipids
from the membrane lipid bilayer [23,24]. Hydroperoxy lipids undergo
secondary decomposition to a number of breakdown products, if not
immediately reduced to the more stable hydroxy compounds [25]. In-
terestingly, the formation of such secondary lipid peroxidation products
(oxo-valeroyl, oxo-glutaryl and oxo-nonanyl containing phospholipids)
was observed during the incubation of red blood cells with PA-LOX
Table 1
Degree of hemolysis and formation of oxygenated PUFAs during the interaction of re-
combinant PA-LOX with isolated human red blood cells. Enzyme preparation and in-
cubations with human red blood cells were carried out as described in Materials and
Methods. After 24 h, cells were spun down and the degree of hemolysis was determined
measuring the hemoglobin content in the supernatant. The lipids were extracted from the
cell pellet and the OH-PUFA/PUFA ratio was quantiﬁed by RP-HPLC as described in the
legend to Fig. 1. The incubations were carried out in triplicate with two diﬀerent batches
of enzyme preparations and we always observed hemolysis. In one of these experiments
the degree of hemolysis and the OH-PUFA/PUFA-ratio were simultaneously determined
and these data are shown in the table.
PA-LOX (μg/ml) Hemolysis (%) OH-PUFA/PUFA ratio (%)
0 0 < 0.1
2 18.6 < 0.1
7 18.1 < 0.1
60 38.6 0.4
170 58.5 4.0
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(Supplemental Fig. S5). Ions with m/z 578 and 634, the formation of
which was initiated by PA-LOX, were conﬁrmed as phosphatidyletha-
nolamine (18:0a/5′-oxo-valeroyl) and phosphatidylethanolamine
(18:0a/9′-oxo-nonanoyl) based on comparison of their mass spectra
with those of synthetic standards (Supplemental Fig. S6). When the
oxidized phospholipids were clustered according to the same algorithm
they are grouped according to their sn2 residues but not according to
their polar head groups. Two major lipid clusters (cluster A, cluster B)
were observed. Cluster A lipids contain mono- (hydroxy, keto) and di-
oxygenated lipids at the sn2-position, while most cluster 2 lipids group
carry truncated fatty acids. When compared with cluster B lipids the
members of cluster A experienced a less pronounced kinetic decline
during the second half of the incubation period (compare PALOX 12 h
and PALOX 24 h). These data suggest that cluster A lipids might be
more stable and/or are less eﬃciently removed from the membranes.
When we statistically compared the relative amounts of oxidized
phospholipids in PA-LOX treated membranes (12 h and 24 h) with the
corresponding control incubations, a robust and statistically highly
signiﬁcant (p < 0.005) increase was observed for most lipid species.
These changes are clearly mirrored in Fig. 6 by the red colored boxes
(right panel). In contrast, the concentration of most non-oxidized
phospholipids decreased during the incubation as indicated by the blue
colored boxes (left panel). This was, however, not the case for the
phospholipids carrying 18:1a/16:0 and 16:0a/18:1 fatty acids. For
these lipids we did not observe signiﬁcant diﬀerences after PA-LOX
treatment (Fig. 6, left panel, 3rd and 4th raw as white colored boxes).
These ﬁndings are not surprising, as neither of these phospholipids are
suitable PA-LOX substrates (no polyenoic fatty acids).
To further explore the erythrocyte lipid network, correlation plots
were generated (Fig. 7). In these plots, lipids are correlated to each
other on the basis of the eﬀect of treatment. When we compared the PA-
LOX substrate lipids at 12 h (PA-LOX vs. control) a strong positive
Fig. 2. Precursor scanning of RBC lipid extracts identiﬁed numerous
phospholipid species that are decreased following PA-LOX treatment.
Human erythrocytes were isolated from healthy volunteers and 100 μl
of packed erythrocytes were incubated in 1 ml PBS in the presence/
absence of 385 μg/ml of PA-LOX for 12 h at 25 °C, followed by lipid
extraction. LC/MS/MS showing precursor scans of control (dashed
line) or PA-LOX treated (solid line) red blood cell lipid extracts.
Spectra were acquired scanning Q1 from 650 to 950 amu, following
direct infusion. Panel A. Identiﬁcation of ions that lose 196 amu in
negative mode, consistent with PE. Panel B. Identiﬁcation of ions that
lose 241 amu in negative mode, consistent with PI. Panel C.
Identiﬁcation of ions that lose 184 amu in positive mode, consistent
with PC. Panel D. Identiﬁcation of ions that lose 87 amu in negative
mode, consistent with PS. Four diﬀerent PA-LOX incubations and two
independent no-enzyme controls were carried out. A representative
precursor scan is shown.
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correlation between most phosphatidylethanolamines and some phos-
phatidylcholines was observed (red colors). In contrast, most phos-
phatidylcholines were strongly negatively correlated with most phos-
phatidylethanolamines (blue colors) indicating, that they behaved
metabolically as diﬀerent groups (Fig. 7A). This was also evident if we
correlated the substrate lipids at 12 h vs. 24 h without PA-LOX treat-
ment (Fig. 7B).
3.4. Membrane lipids of human lung epithelial cell (A549) are also
oxygenated by PA-LOX
P. aeruginosa is the most prevalent chronic infection that contributes
to the pathogenesis of cystic ﬁbrosis [26,27]. The lung injury observed
in these patients involves direct destructive eﬀects induced by the pa-
thogen on lung parenchyma. To test whether recombinant PA-LOX also
attacks the membrane lipids of nucleated cells, we incubated mono-
layers of cultured lung epithelial cells A549 with 50 μg (25 μg/ml),
150 μg (75 μg/ml) and 500 μg (250 μg/ml) of PA-LOX for 12 h and
24 h. Cells were then harvested, washed and membrane lipids
Fig. 3. Precursor ion scanning of RBC lipid extracts iden-
tiﬁed several phospholipids containing linoleic acid and
arachidonic acid that are decreased following PA-LOX
treatment. Human erythrocytes were isolated from healthy
volunteers and 100 μl of packed erythrocytes were in-
cubated in 1 ml PBS in the presence/absence of 385 μg/ml
of PA-LOX for 12 h at 25 °C, followed by lipid extraction.
LC/MS/MS showing precursor scans of control (dashed
line) or PA-LOX treated (solid line) RBC lipid extracts.
Spectra were acquired scanning Q1 from 650 to 950 amu,
following direct infusion. Panel A. Precursor scan of m/z
303.2 shows lipids containing arachidonic acid. Panel B.
Precursor scan of m/z 279.2 shows lipids containing lino-
leic acid. The incubations were carried out in duplicate and
each lipid extract analyzed twice. As indicated in the legend
to Fig. 2 four diﬀerent PA-LOX incubations and two in-
dependent no-enzyme controls were carried out. A re-
presentative precursor scan is shown.
Fig. 4. Precursor scanning of RBC lipid extracts revealed
generation of HETE-PE/PC and HODE-PE/PC following PA-
LOX treatment. Human erythrocytes were isolated from
healthy volunteers and incubated in the presence/absence
of 385 μg of PA-LOX for 12 h at 25 °C, followed by lipid
extraction. LC/MS/MS showing precursor scans of control
(dashed line) or PA-LOX treated (solid line) RBC lipid ex-
tracts. Spectra were acquired, in negative mode, scanning
Q1 from 650 to 950 amu, following direct infusion. Panel A.
Identiﬁcation of ions that generate m/z 319.2 daughter
ions. Panel B. Identiﬁcation of ions that generate m/z 295.1
daughter ions. As indicated in the legend to Fig. 2 four
diﬀerent PA-LOX incubations and two independent no-en-
zyme controls were carried out. A representative precursor
scan is shown.
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extracted. Half of the lipid extracts were hydrolyzed under alkaline
conditions and the OH-PUFA/PUFA-ratio was determined by RP-HPLC.
In control incubations (no enzyme), we quantiﬁed a OH-PUFA/PUFA
ratio of< 0.1 % indicating that< 1 out of 1000 PUFA residues in the
cellular membranes was present as oxidized derivative. This ratio in-
creased to 1.05 % (25 μg/ml), 2.26 % (75 μg/ml) and 3.65 % (250 μg/
ml) in the presence of PA-LOX. Comparing the OH-PUFA/PUFA ratios
of A549 cell oxidation (3.7 %) with the corresponding value of red
blood cell oxidation (19 %, Fig. 1) we concluded that the A549 mem-
brane lipids contain much less oxygenated PUFAs. This ﬁnding might
be related to a lower susceptibility of the A549 plasma membranes, to
more eﬃcient removal and secondary breakdown of oxidized PUFAs or
to lower oxygen concentrations in A549 cells (see Discussion).
The other half of the lipid extract was analyzed by LC-MS/MS to
determine the composition of oxidized phospholipids formed by the
enzyme (Fig. 8). As for the red blood cells, we found that non-oxidized
phospholipids carrying polyenoic fatty acids decreased in a dose-de-
pendent manner. This was observed for shorter (12 h) and longer (24 h)
incubation periods. In contrast, most oxidized phospholipids (Fig. 8,
right panel) increased during that time. As for erythrocytes, we ob-
served lower amounts of oxidized phospholipids at high enzyme con-
centrations and longer incubation periods. This ﬁnding may also be
explained by secondary decomposition of the hydroperoxy inter-
mediates to undetected breakdown products or to phospholipid re-
modeling, which might include the breakdown of oxidized fatty acids.
To judge the extent of lipid peroxide induced secondary reactions in
the A549 cell system we searched our LC-MS/MS data for ions in-
dicating truncated phospholipid species. Interestingly, we hardly found
such ions. Thus, the presence of such ions in the lipid extracts of red cell
incubation but their absence in A549 cell extracts suggested that clea-
vage reactions did occur in red blood cell incubations but not in A549
cells.
3.5. Functional consequences of PA-LOX treatment for A549 cells
When red blood cells were incubated with PA-LOX the cell mem-
branes become leaky and cells undergo hemolysis (Table 1). To explore
the functional impact of PA-LOX treatment for A549 cells, we quanti-
ﬁed the degree of cell detachment and the cellular capacity for trypan
blue exclusion. For this purpose, adherent A549 cells were incubated
for 24 h in the presence and absence of PA-LOX and the results of these
experiments can be summarized as follows (Table 2): i) Only 2 % of
control cells detached during the 24 h incubation period. Although this
number was signiﬁcantly higher (3-times) in the presence of PA-LOX,
the overall degree of cell detachment was still rather low (< 10 %).
These data indicate that more than 90 % of the cells remain attached to
the bottom of the culture dish. ii) The number of “trypan blue positive”
cells in the supernatant increased during PA-LOX treatment (62 % in
the control cells vs. 81 % in PA-LOX treated cells). These data suggest
that PA-LOX reduces the ability of detached A549 cells to exclude
Fig. 5. Eﬀect of puriﬁed PA-LOX on phospholipid compo-
sition of human erythrocytes, following 12 and 24-h in vitro
incubation. Heatmaps were generated using ratio analyte to
internal standard data using the pheatmap package in R.
Levels of treatment response are represented by a color
gradient ranging from blue (decrease in response) to white
(no change) to red (increase in response). Lipids are color-
coded by group and clustered by similarity in overall re-
sponse to PA-LOX. Lipids were normalized to basal levels,
at 12 h. As indicated in the legend to Fig. 2 four diﬀerent
PA-LOX incubations and two independent no-enzyme con-
trols were carried out.
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trypan blue. iii) When we quantiﬁed the share of “trypan blue positive”
cells among adherent cells, we found that more than two thirds of the
PA-LOX treated cells were trypan blue positive. In contrast, < 20 %
trypan blue positive cells were found among adherent cells in control
incubations. These data indicate that PA-LOX treatment impairs the
capacity for trypan blue exclusion. iv) The OH-PUFA/PUFA ratio of the
membrane lipids of PA-LOX treated cells was> 20-fold higher than
that of the control incubations. Here we quantiﬁed an OH-PUFA/PUFA-
ratio of 3.6 %, which is similar to the corresponding value determined
in a previous experiment (Table 1).
It should be noted at this point that failure for trypan blue exclusion
does not necessarily mean cell death but rather transient impairment of
the barrier function of the membrane [28] and we have two in-
dependent lines of experimental evidence that A549 cell did not die
Fig. 6. Alterations in the concentrations of diﬀerent lipid species during PA-LOX treatment of red blood cell membranes. The color code semi-quantitatively mirrors the alterations in lipid
concentrations. Tukey's Honestly Signiﬁcant Diﬀerences post-hoc test was used to compare two groups after one-way analysis of variance. Blue color represents a decrease in the
concentration of a particular lipid species and red color indicates an increase. The signiﬁcances of the diﬀerences (*p < 0.05, **p < 0.005, ***p < 0.0005; t-test) are marked. As
indicated in the legend to Fig. 2 four diﬀerent PA-LOX incubations and two independent no-enzyme controls were carried out.
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during PA-LOX treatment: i) When we compared basic respiration
(oxygen consumption rate, ORC) of A549 cells treated for 24 h with or
without PA-LOX using the Agilent Seahorse XF analyzer we did not
observe signiﬁcant impairment after PA-LOX treatment (ORC of
147.9 ± 30.9 pmoles/min for control incubations vs.
141.1 ± 21.4 pmoles/min after PA-LOX treatment, n > 20,
p= 0.124). ii) PA-LOX treated cells look viable under the microscope
(Fig. 9) and even showed an increased mitosis frequency (see below).
Taken together, these data indicate that treatment of A549 cells
with PA-LOX transiently impairs the barrier function of the plasma
membrane but did not induce major cell lysis. In fact, PA-LOX treated
cells looked healthy under the microscope (Fig. 9).
3.6. PA-LOX treatment enhances mitosis rate of A549 cells
To characterize the structural and functional alterations in more
detail, we performed additional experiments and videotaped the cel-
lular response under the microscope (Supplemental videos). For this
purpose, control (lacking PA-LOX) and PA-LOX containing incubations
Fig. 7. Analysis of selected phospholipid species formed
when A549 cells were treated with puriﬁed PA-LOX. A549
cells were incubated in the presence/absence of varying
amounts of PA-LOX (50 μg, 150 μg, 500 μg/ml) for 12 h
and 24 h. Lipid extracts were analyzed by reverse-phase
LC/MS/MS, in negative mode, using Luna column on
6500 Q Trap. Single incubations were carried out for each
PA-LOX concentration. Each sample was analyzed once by
RP-HPLC and in triplicate LC-MS/MS.
Fig. 8. Confocal light micrographs of cultured A549 cells.
Pre-conﬂuenet A549 cells were incubated in the absence
(panel A) and presence (panel B) of 250 μg/ml pure re-
combinant PA-LOX for 16 h. Four diﬀerent no-enzyme
controls wells and four PA-LOX incubation wells were set
up. Representative images are shown and mitotic cells are
labeled by the asterix.
Table 2
Structural and functional alterations of A549 cells when treated with pure recombinant
PA-LOX. Human lung epithelial cells A549 were seeded in 6-well plates and grown to pre-
conﬂuence in the presence of FCS. Monolayers were gently washed with serum free
DMEM and 2 ml of this medium containing 250 μg/ml of pure PA-LOX was added. After
24 h the supernatant was removed, adherent cells were gently washed with DPBS, scraped
oﬀ and reconstituted in 2 ml DMEM. Detached and adherent cells were counted and
trypan blue staining was performed with small aliquots of the two cell suspensions. From
the remaining cells, the lipids were extracted, hydrolyzed under alkaline conditions and
the OH-PUFA/PUFA-ratio was quantiﬁed as described in Materials and methods. The
experiment was carried out in triplicate and means ± SD are given in the table.
Parameter Control
incubation
PA-LOX
incubation
Signiﬁcance (p)
Cells in supernatant
(%)
2.1 ± 0.7 7.1 ± 1.6 < 0.001
Dead cell in
supernatant (%)
62.6 ± 5.7 81.1 ± 4.0 0.01
Adherent dead cells (%) 19.4 ± 7.1 68.8 ± 2.4 < 0.001
OH-PUFA/PUFA ratio
(%)
0.17 ± 0.09 3.6 ± 0.4 < 0.001
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Fig. 9. Correlation analysis of diﬀerent PA-LOX substrate
lipids present in erythrocyte membranes. A) Correlations
among fold changes of diﬀerent PA-LOX substrate lipids
after treatment of human erythrocytes for 12 h in the pre-
sence and absence of PA-LOX. B) Correlations among fold
changes of diﬀerent PA-LOX substrate lipids after 12 h and
24 h treatment of human erythrocytes in the absence of PA-
LOX. Red color indicates strong positive correlation; the
brighter the red color, the stronger positive correlations.
Blue color indicates strong negative correlation; the
brighter the blue color, the stronger negative correlations.
The area of each circle symbolizes the absolute value of its
corresponding correlation. As indicated in the legend to
Fig. 2 four diﬀerent PA-LOX incubations and two in-
dependent no-enzyme controls were carried out. A re-
presentative precursor scan is shown.
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(250 μg/ml) were set up in diﬀerent 6-well plates. Pictures were taken
every 5 min for the ﬁrst hour of incubation and then every 15 min
during the remaining 15 h. Altogether four videos were recorded for
both, control (Supplemental videos 1–4) and PA-LOX (Supplemental
videos 5–8) incubations. When we compared the overall shape of the
cells in the PA-LOX sample and the cells in the control incubation, we
did not observe major structural alterations. We speciﬁcally searched
for morphological signs of cell lysis but could not ﬁnd any over the
entire duration of the incubation period. However, while screening the
videos we got the impression that in PA-LOX treated cells the rate of cell
division (mitosis) was increased. This subjective impression prompted
us to speciﬁcally quantify mitosis frequencies. For this, we counted
mitotic events and found 3.60 ± 3.15 per visualization spot in the
control incubations. In contrast, 6.36 ± 1.81 mitosis events were seen
in the PA-LOX treated sample. Statistical evaluation of these numbers
revealed an 85 % increase in the mitosis rate and this diﬀerence was
highly signiﬁcant (p < 0.001).
4. Discussion
4.1. PA-LOX exhibits membrane oxygenase activity
PA is a facultative pathogen, which frequently infects im-
munocompromized patients [4,27]. It is one of the rare bacterial species
carrying a LOX gene and uniquely the corresponding enzyme is secreted
into the extracellular space [5]. The enzyme interacts in vitro with
phospholipid vesicles [11] and when incubated with human ery-
throcytes it induces hemolysis [13]. Previous in vitro experiments in-
dicated the formation of speciﬁcally oxygenated PUFAs during PA-LOX-
phospholipid interaction [8,13], but the structures of the oxidized es-
terlipids have not been identiﬁed. Employing a lipidomic approach we
detected a large array of oxidized phospholipids during in vitro inter-
action of puriﬁed PA-LOX with intact red blood cells (Fig. 6). Similar
results were obtained, when cultured human alveolar epithelial cells
were used as substrate (Fig. 8) but here lower amounts of oxidation
products were formed. These data indicate for the ﬁrst time the for-
mation of oxygenated phospholipids during the interaction of PA-LOX
with nucleated and non-nucleated mammalian cells.
From a structural point of view, PA-LOX is custom-made for phos-
pholipid oxidation. All crystal structures of this enzyme [PDB 4G32
(1.75 Å), 4G33 (2.03 Å), 5IR4 (1.48 Å), 5IR5 (1.9 Å), 4RPE, (1.60 Å),
5LC8 (1.80 Å)] indicate a bifurcated substrate-binding pocket, which
consists of two sub-cavities (sub-cavity 1 and 2) and an upstream lobby.
The shape of this substrate-binding pocket is unique among LOXs [29]
and when the enzyme is expressed in E. coli an endogenous phospho-
lipid ligand has been localized in this pocket [8,11,12]. The polar head
group of this ligand is bound in the lobby and the two fatty acids are
accommodated each in one of the two sub-cavities. This is an ideal
structural basis for phospholipid binding and phospholipid oxidation.
In fact, when endogenous ligand, which does not carry PUFA residues,
is replaced by a PUFA containing phospholipid, the replacing ligand
should quickly be oxidized.
4.2. Mechanism of PA-LOX initiated membrane lipid oxidation
Originally [13], it was suggested that membrane oxidation might
render red blood cell membranes leaky, causing hemolysis. However,
our new data indicate that hemolysis occurs even in the absence of
signiﬁcant membrane oxidation (Table 1). Similar results have been
reported for the interaction of rabbit ALOX15 with biomembranes [30].
These studies have indicated that the enzyme ﬁrst integrates into the
lipid bilayer of intracellular membranes allowing the release of proteins
from organelle lumens [31]. These processes have been implicated in
the maturational breakdown of mitochondria during reticulocyte-ery-
throcyte transition [32,33]. A similar mechanism might be involved in
PA-LOX-erythrocyte interaction. During the initial phase of incubation,
the enzyme might integrate into the lipid bilayer so that the membrane
becomes leaky. At later stages, the enzyme may then oxygenate the
membrane lipids, which further damages the barrier function of the
plasma membrane. In a third stage, the hydroperoxy lipids formed by
PA-LOX might undergo secondary decomposition via hemoglobin cat-
alyzed hydroperoxidase reactions [34,35]. The detection of truncated
phospholipids in lipid extracts of PA-LOX treated erythrocytes may be
considered as indicator for such heme-catalyzed secondary peroxidase
reactions.
4.3. Oxidation susceptibility of diﬀerent types of membranes
When we compared the degree of membrane phospholipid oxida-
tion of erythrocytes and A549 cells we found that erythrocyte mem-
brane lipids are more heavily oxidized. This result was somewhat sur-
prising since a rough estimate of the cell numbers in the two assays
indicated that the PA-LOX load of each A549 cell was more than two
orders of magnitude higher than for each erythrocyte. Although we
added the same amount of enzyme the A549 cell incubation involved
roughly 5 × 106 cells whereas 109 erythrocytes were present in the red
cell incubation mixture. On the other hand, A549 cells are much bigger
than erythrocytes and thus, the phospholipid content per cell is much
higher. Moreover, the phospholipid composition of the two cell types
may be diﬀerent, which is likely to impact PA-LOX susceptibility of
diﬀerent cell types.
Although the molecular basis for this diﬀerence has not been ex-
plored in detail several factors may contribute: i) Erythrocyte mem-
branes might constitute more suitable substrates for PA-LOX. The
higher susceptibility might be related to diﬀerences in the chemical
composition of the membranes but also to the higher oxygen con-
centrations in erythrocytes. Owing to the high hemoglobin content of
erythrocytes (20 mM) the oxygen concentration in these cells is more
than two orders of magnitude higher than in most other cells. Such high
oxygen concentrations augment the catalytic activity of PA-LOX since
its oxygen aﬃnity is rather low [Km of 406 μM, [12]]. When acting on
nucleated cells (oxygen concentrations of 170 μM) the enzyme is not
working at oxygen saturation and thus, its catalytic activity is limited.
In contrast, when acting on erythrocytes (oxygen concentration of
20 mM) the enzyme is oxygen saturated and thus, it works under Vmax
conditions. ii) The extent of heme-catalyzed hydroperoxidase reactions,
which convert the PA-LOX derived hydroperoxy lipids to secondary
lipid peroxidation products, is higher in erythrocytes. iii) The repair
capacity of erythrocytes for oxidative damage is limited. Metabolically,
erythrocytes are rather simple cells, which are more susceptible to ex-
ternal oxidative stress when compared to nucleated cells [23]. They
have a limited energy metabolism (absence of mitochondria), they lack
the biosynthetic capacity for fatty acids (no fatty acid synthases, de-
saturases and elongases) and they are not capable of synthesizing
phospholipids (lack of endoplasmic reticulum). There is a small capa-
city for membrane lipid remodeling (deacylation-reacylation cycles do
occur) but oxygenated fatty acids cannot be degraded (no mitochon-
dria, no peroxisomes). In summary, red blood cells exhibit a reduced
capacity to repair oxidative membrane damage and thus, oxidized
membrane lipids may accumulate. In contrast, nucleated cells have a
much more eﬃcient energy metabolism (oxidative phosphorylation
instead of glycolysis) and they exhibit active fatty acid and phospho-
lipid synthesizing capacities. Moreover, oxidized fatty acids can be re-
moved from the membrane phospholipids and can be degraded via
peroxisomal and/or mitochondrial β-oxidation.
To test the impact of heme-catalyzed lipid peroxidation on PA-LOX
induced erythrocyte membrane oxidation we prepared erythrocyte
ghosts and used them as substrate for the enzyme. Unfortunately, when
we analyzed the OH-PUFA/PUFA ratio of our ghost preparations we
observed a high degree of membrane lipid oxidation (2.2 %). In con-
trast, the corresponding value for intact erythrocytes was about 0.1 %.
These data suggested that non-enzymatic lipid peroxidation must have
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taken place during ghost preparation. Consequently, the structure of the
ghost membranes should be quite diﬀerent when compared with that of
intact red cells. Thus, direct comparison might not be possible.
Nevertheless, when we incubated these ghosts with PA-LOX we ob-
served an increase in the OH-PUFA/PUFA ratio (3.7 %) but the product
speciﬁcity was clearly lower (large share of autooxidation products in
RP-HPLC).
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbalip.2017.11.005.
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